<DOC>
	<DOCNO>NCT00569842</DOCNO>
	<brief_summary>Currently , accurate way predict occurrence Graft v Host Disease ( GvHD ) infection . The purpose study analyze blood ImmuKnow® Assay see doctor detect patient risk GvHD get infection occur .</brief_summary>
	<brief_title>Investigation Cylex® ImmuKnow® Assay</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<criteria>Patients undergo allogeneic HSCT use myeloablative preparative regimen follow disorder eligible : 1 . Acute leukemia 2 . NonHodgkin 's Lymphoma 3 . Chronic lymphocytic leukemia 4 . Hodgkin 's disease 5 . Multiple myeloma 6 . Myelodysplastic Syndromes 7 . Myeloproliferative Disorders 8 . Aplastic Anemia 9 . Chronic myelogenous leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>